Business Context and Reporting Period
Company: Gyre Therapeutics, Inc. (GYRE)
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2026
Event: Completion of the acquisition of Cullgen Inc. via a merger with Helix Merger Sub Corp. Cullgen continues as a wholly-owned subsidiary of Gyre.
Key Financial Metrics and Transaction Details
- Transaction Value: Approximately $300 million (all-stock transaction).
- Accounting Treatment: Treated as a combination of entities under common control (both controlled by GNI Group Ltd.). Assets and liabilities recognized at historical carrying amounts; financial statements will be retrospectively adjusted.
- Consideration Structure:
- Designated holders received Gyre Series B Convertible Preferred Stock (convertible into 5 shares of Common Stock).
- Other holders received Gyre Common Stock based on an exchange ratio of 0.4753.
- Issuance capped at 19.99% of outstanding Common Stock/voting power prior to stockholder approval of the conversion proposal.
- Financial Statements: Cullgen's financial statements and pro forma combined information are not included in this filing but will be filed in an amendment.
Material Changes and Corporate Actions
Leadership Changes
- Resignations: Thomas Eastling and Songjiang Ma resigned from the Board. Songjiang Ma also resigned as President. Ruoyu Chen resigned as Chief Financial Officer (CFO).
- Appointments:
- Ying Luo, Ph.D. appointed as Chief Executive Officer, President, and Class I Director.
- Thomas Eastling appointed as Chief Financial Officer.
- Ping Zhang continues as Chairman of the Board.
- Board Size: Reduced to seven directors.
Equity and Governance
- Stockholder Meeting: Scheduled for June 10, 2026, to approve the conversion of Series B Preferred Stock into Common Stock.
- Employee Equity: In-the-money Cullgen options converted to Gyre options; out-of-the-money options cancelled; RSUs vested and settled for Gyre Common Stock.
Outlook, Risks, and Contingencies
- Conversion Proposal: The ability to convert Series B Preferred Stock into Common Stock is contingent upon stockholder approval at the June 10, 2026 meeting.
- Forward-Looking Statements: The filing contains statements regarding the timing of stockholder approval and the filing of resale registration statements, which are subject to risks and uncertainties.
- Regulatory Compliance: The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.
Investor Verification Checklist
- Verify the outcome of the stockholder meeting on June 10, 2026, regarding the Conversion Proposal.
- Review the upcoming amendment to this 8-K for Cullgen's financial statements and pro forma combined financial information.
- Confirm the final exchange ratio and share issuance details once the conversion proposal is approved.
- Monitor the filing of the resale registration statement pursuant to the Registration Rights Agreement.